HIV-1 inhibitor-6

Cat. No.: HY-134851 Purity: 98.91%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

HIV-1 inhibitor-6 (compound 9), a diheteroarylamide-based compound, is a potent HIV-1 pre-mRNA alternative splicing inhibitor. HIV-1 inhibitor-6 blocks HIV replication. HIV-1 inhibitor-6 is active against wild-type HIV-1IIIB (subtype B, X4-tropic) and HIV-1 97USSN54 (subtype A, R5-tropic) with EC₅₀s of 0.6 μM and 0.9 μM, respectively. HIV-1 inhibitor-6 inhibits HIV strains resistant to agents targeting HIV reverse transcriptase, protease, integrase, and coreceptor CCR5 with EC₅₀s ranging from 0.9 to 1.5 μM.

For research use only. We do not sell to patients.

HIV-1 inhibitor-6 Chemical Structure

CAS No. : 1821309-39-0

Size	Price	Stock	Quantity
5 mg	USD 350	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 600	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 1150	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 1800	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 2850	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE HIV-1 inhibitor-6

•Cancer Commun (Lond). 2024 Sep 2. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

X4 HIV-1 (III_B)

0.6 μM (EC₅₀)

R5 HIV-1

0.9 μM (EC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	> 100 μM Compound: 9; 1C8	Cytotoxicity against GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 assessed as cell viability at after 24 hrs by Guava viacount assay Cytotoxicity against GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 assessed as cell viability at after 24 hrs by Guava viacount assay	[PMID: 26878150]
CCRF-CEM	EC₅₀	0.6 μM Compound: 9; 1C8	Antiviral activity against subtype B X4 tropic HIV1 3B infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days Antiviral activity against subtype B X4 tropic HIV1 3B infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days	[PMID: 26878150]
CCRF-CEM	EC₅₀	0.9 μM Compound: 9; 1C8	Antiviral activity against subtype A R5 tropic HIV1 97USSN54 infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days Antiviral activity against subtype A R5 tropic HIV1 97USSN54 infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days	[PMID: 26878150]
CCRF-CEM	EC₅₀	0.9 μM Compound: 9; 1C8	Antiviral activity against maraviroc-resistant HIV1 BAL R5 harboring envelop V3 A19T/L20F/T22A/E25D/126V mutant infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days Antiviral activity against maraviroc-resistant HIV1 BAL R5 harboring envelop V3 A19T/L20F/T22A/E25D/126V mutant infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days	[PMID: 26878150]
CCRF-CEM	EC₅₀	1.3 μM Compound: 9; 1C8	Antiviral activity against NNRTI-resistance HIV1 E00443 harboring reverse transcriptase D67N/K70R/Y115F/Q151M/M184V/K219Q mutant infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days Antiviral activity against NNRTI-resistance HIV1 E00443 harboring reverse transcriptase D67N/K70R/Y115F/Q151M/M184V/K219Q mutant infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days	[PMID: 26878150]
CCRF-CEM	EC₅₀	1.4 μM Compound: 9; 1C8	Antiviral activity against PI-resistant HIV1 isolate 2948 harboring protease G48V/L90M mutant infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days Antiviral activity against PI-resistant HIV1 isolate 2948 harboring protease G48V/L90M mutant infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days	[PMID: 26878150]
CCRF-CEM	EC₅₀	1.5 μM Compound: 9; 1C8	Antiviral activity against INI-resistant HIV1 isolate 11845 harboring integrase G140S/Q148H mutant infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days Antiviral activity against INI-resistant HIV1 isolate 11845 harboring integrase G140S/Q148H mutant infected in GFP-positive human CEM cells expressing CD4+,CXCR4 and CCR5 after 3 days	[PMID: 26878150]

Molecular Weight

330.32

Formula

C₁₄H₁₀N₄O₄S

CAS No.

1821309-39-0

Appearance

Solid

Color

Yellow to orange

SMILES

O=C(C1=CN(C)C=CC1=O)NC2=NSC3=C2C=C([N+]([O-])=O)C=C3

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 3.33 mg/mL (10.08 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0274 mL	15.1368 mL	30.2737 mL
5 mM	0.6055 mL	3.0274 mL	6.0547 mL
10 mM	0.3027 mL	1.5137 mL	3.0274 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 98.91%

Select Batch:

Data Sheet (275 KB) SDS (251 KB)

COA (254 KB) HNMR (269 KB) LCMS (269 KB)

Handling Instructions (2659 KB)

References

[1]. Peter K Cheung, et al. A Parallel Synthesis Approach to the Identification of Novel Diheteroarylamide-Based Compounds Blocking HIV Replication: Potential Inhibitors of HIV-1 Pre-mRNA Alternative Splicing. J Med Chem. 2016 Mar 10;59(5):1869-79. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.0274 mL	15.1368 mL	30.2737 mL	75.6842 mL
	5 mM	0.6055 mL	3.0274 mL	6.0547 mL	15.1368 mL
	10 mM	0.3027 mL	1.5137 mL	3.0274 mL	7.5684 mL

HIV-1 inhibitor-6 Related Classifications

Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

HIV-1 inhibitor-61821309-39-0HIVHuman immunodeficiency virusDiheteroarylamideHIV-1pre-mRNA alternative splicingreplicationHIV-1IIIBX4-tropic97USSN54R5-tropicreverse transcriptaseproteaseintegrasecoreceptor CCR5Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

HIV-1 inhibitor-6

Customer Review

HIV-1 inhibitor-6 Related Antibodies

1 Publications Citing Use of MCE HIV-1 inhibitor-6

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

HIV-1 inhibitor-6 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report